Bioanalysis during pregnancy: recent advances and novel sampling strategies

Papers of special note have been highlighted as: •• of considerable interest

References

• 1 White SM. The effect of controlled drugs on the unborn child and fetus. J. Cin. Forensic Med. 8, 129–139 (2001).
  Medline CASGoogle Scholar
• 2 Sithisarn T, Granger DT, Bada HS. Consequences of prenatal substance use. Int. J. Adolesc. Med. Health 24, 105–112 (2012).
  MedlineGoogle Scholar
• 3 Finnegan LP. Women, pregnancy and methadone. Heroin Add. Rel. Cin. Probl. 2, 1–8 (2000).
  Google Scholar
• 4 Huestis MA, Choo RE. Drug abuse's smallest victims: in utero drug exposure. Forensic Sci. Int. 128, 20–30 (2002).
  MedlineGoogle Scholar
• 5 Wilcox AJ, Weinberg CR, Baird DD. Risk factors for early pregnancy loss. Epidemiology 1, 382–385 (1990).
  Medline CASGoogle Scholar
• 6 Cruz A, Bouzas CA, Concheiro M et al. Drogas y Teratogenia. Adicciones 18(1), 1–18 (2006).
  Google Scholar
• 7 Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Substance Abuse and Mental Health Services Administration, MD, USA (2013).
  Google Scholar
• 8 Observatorio Español de la Droga y las Toxicomanías. Informe 2011. Situación y tendencias de los problemas de la drogas en España. www.pnsd.msssi.gob.es.
  Google Scholar
• 9 Ostrea EM Jr, Knapp DK, Tannenbaum L et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J. Pediatr. 138, 344–348 (2001).
  Medline CASGoogle Scholar
• 10 Friguls B, Joya X, Garica-Serra J et al. Assessment of exposure to drugs of abuse during pregnancy by hair analysis in a Mediterranean island. Addiction 107, 1471–1479 (2012).
  MedlineGoogle Scholar
• 11 Gray T, Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Anal. Bioanal. Chem. 388, 1455–1465 (2007).
  Medline CASGoogle Scholar
• 12 Lozano J, Garcia-Algar O, Vall O et al. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther. Drug Monit. 29, 711–734 (2007).
  Medline CASGoogle Scholar
• 13 Gallardo E, Queiroz JA. The role of alternative specimens in toxicological analysis. Biomed. Chromatogr. 22, 795–821 (2008).
  Medline CASGoogle Scholar
• 14 Płotka J, Narkowicz S, Polkowska Ż et al. Effects of addictive substances during pregnancy and infancy and their analysis in biological materials. In: Reviews of Environmental Contamination and Toxicology, Volume 227. Whitacre DM (Ed.). Springer International Publishing, Switzerland, 55–77 (2014).
  Google Scholar
• 15 Ungerer M, Knezovich J, Ramsay M. In utero alcohol exposure, epigenetic changes, and their consequences. Alcohol Res. 35(1), 37–46 (2013).
  MedlineGoogle Scholar
• 16 Behnke M, Smith VC. Comitee on substance abuse and Comitte on Fetus and Newborn. Prenatal substance abuse: short and long-term effects on the exposed fetus. Pediatrics 131(3), e1009–10024 (2014).
  Google Scholar
• 17 Clave S, Joya X, Salat-Batlle J et al. Ethanol cytotoxic effect on trophoblast cells. Toxicol. Lett. 225(2), 216–221 (2014).
  Medline CASGoogle Scholar
• 18 Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 134, e547 (2014).•• Complete description and analysis of the neonatal abstinence syndrome from a clinical and toxicological point of view.
  MedlineGoogle Scholar
• 19 Stanhope TJ, Gill LA, Rose C. Chronic opioid use during pregnancy: maternal and fetal implications. Clin. Perinatol. 40(3), 509–524 (2013).
  MedlineGoogle Scholar
• 20 Cleary BJ, Donnelly J, Strawbridge J et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 105(12), 2071–2084 (2010).
  MedlineGoogle Scholar
• 21 Reddy AM, Harper RG, Stern G. Observations on heroin and methadone withdrawal in the newborn. Pediatrics 48(3), 353–358 (1971).
  Medline CASGoogle Scholar
• 22 Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr. Dis. Treat. 9, 1257–1266 (2013).
  MedlineGoogle Scholar
• 23 Mactier H. Neonatal and longer term management following substance misuse in pregnancy. Early Hum. Dev. 89(11), 887–892 (2013).
  MedlineGoogle Scholar
• 24 Jones HE, Kaltenbach K, Heil SH et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 363(24), 2320–2331 (2010).
  Medline CASGoogle Scholar
• 25 Díaz SD, Smith LM, Lagasse LL et al. Effects of prenatal methamphetamine exposure on behavioral and cognitive findings at 7.5 years of age. J. Pediatr. 164(6), 1333–1338 (2014).
  Medline CASGoogle Scholar
• 26 Buckingham-Howes S, Berger SS, Scaletti LA, Black MM. Systematic review of prenatal cocaine exposure and adolescent development. Pediatrics 131(6), e1917–e1936 (2013).
  MedlineGoogle Scholar
• 27 Ackerman JP, Riggins T, Black MM. A review of the effects of prenatal cocaine exposure among school-aged children. Pediatrics 125(3), 554–565 (2010).
  MedlineGoogle Scholar
• 28 Minnes S, Singer L, Min MO. Effects of prenatal cocaine/polydrug exposure on substance use by age 15. Drug Alcohol Depend. 134, 201–210 (2014).
  MedlineGoogle Scholar
• 29 Müller KU, Menningen E, Ripke S et al. Altered reward processing in adolescents with prenatal exposure to maternal cigarette smoking. JAMA Psychiatry 70(8), 847–856 (2013).
  MedlineGoogle Scholar
• 30 Vassoler FM, Byrnes EM, Pierce RC. The impact of exposure to addictive drugs on future generations: physiological and behavioral effects. Neuropharmacology 76, 269–275 (2014).
  Medline CASGoogle Scholar
• 31 Child Welfare Information Gateway. U.S. Department of Health and Human Services. (2012). www.childwelfare.gov/systemwide/laws_policies/statutes/drugexposed.pdf.
  Google Scholar
• 32 Concheiro M, González-Colmenero E, Lendoiro E et al. Alternative matrices for cocaine, heroin, and methadone in utero drug exposure detection. Ther. Drug Monit. 35(4), 502–509 (2013).•• Comparison of maternal hair, meconium, placenta and umbilical cord for the detection of in utero drug exposure and description of multi-analyte methods.
  Medline CASGoogle Scholar
• 33 Kacinko SL, Jones HE, Johnson RE, Choo RE et al. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Cin. Pharmacol. Ther. 84, 604–12 (2008).
  Medline CASGoogle Scholar
• 34 Casanova OQ, Lombardero N, Behnke M et al. Detection of cocaine exposure in the neonate. Analyses of urine, meconium, and amniotic fluid from mothers and infants exposed to cocaine. Arch. Pathol. Lab. Med. 118, 988–93 (1994).
  Medline CASGoogle Scholar
• 35 Moller M, Karaskov T, Koren G. Opioid detection in maternal and neonatal hair and meconium: characterization of an at-risk population and implications to fetal toxicology. Ther. Drug Monit. 32, 318–323 (2010).
  Medline CASGoogle Scholar
• 36 Garcia-Boumissen, Rokach B, Karaskov T et al. Methamphetamine detection in maternal and neonatal hair: implication for fetal safety. Arch. Dis. Child Fetal Neonatal Ed. 92, 351–355 (2007).
  Google Scholar
• 37 de Castro A, Jones HE, Johnson RE et al. Methadone, cocaine, opiates, and metabolites disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes. Ther. Drug Monit. 33, 443–452 (2011).
  Medline CASGoogle Scholar
• 38 Concheiro M, Jones HE, Johnson RE et al. Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose and neonatal outcomes. J. Anal. Toxicol. 34, 498–505 (2010).
  Medline CASGoogle Scholar
• 39 Montgomery D, Plate C, Alder SC et al. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. J. Perinatol. 26, 11–14 (2006).
  Medline CASGoogle Scholar
• 40 Moore CM, Brown S, Negrusz A et al. Determination of cocaine and its major metabolite, benzoylecgonine, in amniotic fluid, umbilical cord blood, umbilical cord tissue, and neonatal urine: a case study. J. Anal. Toxicol. 17(1), 62 (1993).
  Medline CASGoogle Scholar
• 41 Winecker RE, Goldberger BA, Tebbett I et al. Detection of cocaine and its metabolites in amniotic fluid and umbilical cord tissue. J. Anal. Toxicol. 21, 97–104 (1997).
  Medline CASGoogle Scholar
• 42 de Castro A, Jones HE, Johnson RE et al. Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. Clin. Chem. 57, 449–458 (2011).
  Medline CASGoogle Scholar
• 43 Concheiro M, Jones HE, Johnson RE et al. Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes. Ther. Drug Monit. 32, 206–215 (2010).
  Medline CASGoogle Scholar
• 44 Falcon M, Pichini S, Joya J et al. Maternal hair testing for the assessment of fetal exposure to drug of abuse during early pregnancy: comparison with testing in placental and fetal remains. Forensic Sci. Int. 218, 92–96 (2012).
  Medline CASGoogle Scholar
• 45 Garcia-Algar O, Lopez-Vilchez MA, Martin I et al. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Cin. Toxicol. 45, 295–298 (2007).
  Medline CASGoogle Scholar
• 46 Martin I, Lopez-Vilchez MA, Mur A et al. Neonatal withdrawal syndrome after chronic maternal drinking of mate. Ther. Drug Monit. 29, 127–129 (2007).
  Medline CASGoogle Scholar
• 47 Garcia-Algar O, Vall O, Alameda F et al. Prenatal exposure to arecoline (areca nut alkaloid) and birth outcomes. Arch. Dis. Child Fetal Neonatal Ed. 90, F276–F277 (2005).
  Medline CASGoogle Scholar
• 48 US Department of Health and Human Services, Food and Drug Administration. Mass Spectrometry for Confirmation of the Identity of Animal Drug Residues. (2003). www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm052658.pdf.
  Google Scholar
• 49 European Union Decision 2002/657/EC (17/8/2002). Off. J. Eur. Commun. 221, 8–36 (2002).
  Google Scholar
• 50 Scientific Working Group for Forensic Toxicology (SWGTOX). Standard practices for method validation in forensic toxicology. J. Anal. Toxicol. 37, 452–474 (2013).•• Complete guidelines for analytilcal method validation.
  MedlineGoogle Scholar
• 51 Bakdash A, Burger P, Goecke TW et al. Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study. Anal. Bioanal. Chem. 396, 2469–2477 (2010).
  Medline CASGoogle Scholar
• 52 Hastedt M, Krumbiegel F, Gapert R et al. Fatty acid ethyl esters (FAEEs) as markers for alcohol in meconium: method validation and implementation of a screening program for prenatal drug exposure. Forensic Sci. Med. Pathol. 9, 287–295 (2013).
  Medline CASGoogle Scholar
• 53 Himes SK, Concheiro M, Scheidweiler KB et al. Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC–MS/MS quantification. Anal. Bioanal. Chem. 406(7), 1945–1955 (2014).•• Challenging method for the simultaneous determination of the alcohol biomarkers ethyl-glucuronide, ethyl-sulfate and fatty acid ethyl esters in meconium.
  Medline CASGoogle Scholar
• 54 Cabarcos P, Tabernero MJ, Álvarez I et al. A new method for quantifying prenatal exposure to ethanol by microwave-assisted extraction (MAE) of meconium followed by gas chromatography-mass spectrometry (GC–MS). Anal. Bioanal. Chem. 404, 147–155 (2012).
  Medline CASGoogle Scholar
• 55 Hutson JR, Rao C, Fulga N et al. An improved method for rapidly quantifying fatty acid ethyl esters in meconium suitable for prenatal alcohol screening. Alcohol 45, 193–199 (2011).
  Medline CASGoogle Scholar
• 56 Tarcomnicu I, van Nuijs ALN, Aerts K et al. Ethyl glucuronide determination in meconium and hair by hydrophilic interaction liquid chromatography-tandem mass spectrometry. Forensic Sci. Int. 196, 121–127 (2010).
  Medline CASGoogle Scholar
• 57 Roehsig M, Mendes Louzada de Paula D, Moura S et al. Determination of eight fatyy acid ethyl esters in meconium samples by headspace solid-phase microextraction and gas chromatography-mass spectrometry. J. Sep. Sci. 33, 2115–2122 (2010).
  Medline CASGoogle Scholar
• 58 Kwak HS, Kang YS, Han KO et al. Quantitation of fatty acid ethyl esters in human meconium by an improved liquid chromatography/tandem mass spectrometry. J. Chromatogr. B 878, 1871–1874 (2010).
  Medline CASGoogle Scholar
• 59 Bakdash A, Burger P, Goecke TW et al. Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study. Anal. Bioanal. Chem. 396, 2469–2477 (2010).
  Medline CASGoogle Scholar
• 60 Morini L, Marchei E, Pellegrini M et al. Liquid chromatography with tandem mass spectrometric detection for the measurement of ethyl glucuronide and ethyl sulfate in meconium: new biomarkers of gestational ethanol exposure. Ther. Drug Monit. 30, 725–732 (2008).
  Medline CASGoogle Scholar
• 61 Gray TR, Barnes AJ, Huestis MA. Effect of hydrolysis on identifying prenatal cannabis exposure. Anal. Bioanal. Chem. 397, 2335–2347 (2010).
  Medline CASGoogle Scholar
• 62 Marin SJ, Coles R, Urry FM et al. Confirmation of cannabinoids in meconium using two-dimensional gas chromatography with mass spectrometry detection. J. Chromatogr. B 858, 59–64 (2007).
  Medline CASGoogle Scholar
• 63 Marin SJ, Coles R, Merrell M et al. Quantitation of benzodiazepines in urine, serum, plasma, and meconium by LC–MS–MS. J. Anal. Toxicol. 32, 491–498 (2008).
  Medline CASGoogle Scholar
• 64 Kelly T, Gray TR, Huestis M. Development and validation of a liquid-chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method of simultaneous analysis of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxymethamphetamine-related (MDMA) analytes in human meconium. J. Chromatogr. B 867, 194–204 (2008).
  Medline CASGoogle Scholar
• 65 Gunn JA, Sweeney B, Dahn T et al. Simultaneous quantification of amphetamine and methamphetamine in meconium using ISOLUTE® HM-N-supported liquid extraction columns and GC–MS. J. Anal. Toxicol. 32, 485–490 (2008).
  Medline CASGoogle Scholar
• 66 Kacinko SL, Shakleya DM, Huestis MA. Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium. Anal. Chem. 80, 246–252 (2008).
  Medline CASGoogle Scholar
• 67 de Carvalho Mantovani C, Bittar Lima M, Rodrigues de Oliveira CD et al. Development and practical application of accelerated solvent extraction for the isolation of cocaine/crack biomarkers in meconium samples. J. Chromatogr. B 957, 14–23 (2014).
  MedlineGoogle Scholar
• 68 Coles R, Kushnir MM, Nelson GJ et al. Simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, oxycodone, and 6-acetylmorphine in urine, serum, plasma, whole blood, and meconium by LC–MS/MS. J. Anal. Toxicol. 31, 1–14 (2007).
  Medline CASGoogle Scholar
• 69 Marin SJ, Christensen RD, Baer VL et al. Nicotine and metabolites in paired umbilical cord tissue and meconium specimens. Ther. Drug Monit 33, 80–85 (2011).
  Medline CASGoogle Scholar
• 70 Gray TR, Shakleya DM, Huestis MA. Quantification of nicotine, cotinine, trans-3′-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry. J. Chromatogr. B 863, 107–114 (2008).
  Medline CASGoogle Scholar
• 71 Mozaner Bordin DC, Alves MNR, Cabrices OG et al. A rapid assay for the simultaneous determination of nicotine, cocaine and metabolites in meconium using disposable pipette extraction and gas chromatography-mass spectrometry (GC–MS). J. Anal. Toxicol. 38, 31–38 (2014).
  Medline CASGoogle Scholar
• 72 López P, Bermejo AM, Tabernero MJ et al. Cocaine and opiates use in pregnancy: detection of drugs in neonatal meconium and urine. J. Anal. Toxicol. 33, 351–355 (2009).
  Medline CASGoogle Scholar
• 73 Gray TR, Shakleya DM, Huestis MA. A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal. Bioanal. Chem. 393, 1977–1990 (2009).
  Medline CASGoogle Scholar
• 74 Pichini S, Morini L, Pacifici R et al. Development of a new immunoassay for the detection of ethyl glucuronide (EtG) in meconium: validation with authentic specimens analyzed using LC–MS/MS. Preliminary results. Clin. Chem. Lab. Med. doi: 10.1515/cclm-2013–1087 (2014) (Epub ahead of print).
  Google Scholar
• 75 Marin SJ, Merrell M, McMillin GA. Drugs of abuse detection in meconium: a comparison between ELISA and biochip microarray. J. Anal. Toxicol. 35, 40–45 (2011).
  Medline CASGoogle Scholar
• 76 Marin SJ, Keith L, Merrell M et al. Comparison of drugs of abuse detection in meconium by EMIT®II and ELISA. J. Anal. Toxicol. 33, 148–154 (2009).
  Medline CASGoogle Scholar
• 77 Ristimaa J, Gergov M, Pelander A et al. Broad-spectrum drug screening of meconium by liquid chromatography with tandem mass spectrometry and time-of-flight mass spectrometry. Anal. Bioanal. Chem. 398, 925–935 (2010).
  Medline CASGoogle Scholar
• 78 Nanovskaya T, Deshmukh S, Brooks M et al. Transplacental transfer and metabolism of buprenorphine. J. Pharmacol. Exp. Ther. 300(1), 26–33 (2002).
  Medline CASGoogle Scholar
• 79 Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human Placenta. Clin. Pharmacokinet 43(8), 487–514 (2004).
  Medline CASGoogle Scholar
• 80 de Castro A, Díaz A, Piñeiro B et al. Simultaneous determination of opiates, methadone, amphetamines, cocaine, and metabolites in human placenta and umbilical cord by LC–MS/MS. Anal. Bioanal. Chem. 405(12), 4295–4305 (2013).
  Medline CASGoogle Scholar
• 81 Matlow JN, Aleksa K, Lubetsky A et al. The detection and quantification of ethyl glucuronide in placental tissue perfusate by headspace solid-phase microextraction coupled with gas chromatography-mass spectrometry. J. Popul Ther. Cin. Pharmacol 19(3), e473–e482 (2012).
  MedlineGoogle Scholar
• 82 Morini L, Falcón M, Pichini S et al. Ethyl-glucuronide and ethyl-sulfate in placental and fetal tissues by liquid chromatography couple with tandem mass spectrometry. Anal. Biochem. 418, 30–36 (2011).
  Medline CASGoogle Scholar
• 83 Concheiro-Guisan M, Shakleya DM, Huestis MA. Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry. Anal. Bioanal. Chem. 394, 513–522 (2009).
  Medline CASGoogle Scholar
• 84 Joya X, Pujadas M, Falcón M et al. Gas chromatography-mass spectrometry assay for the simultaneous quantification of drugs of abuse in human placenta at 12^th week of gestation. Forensic Sci. Int 196, 38–42 (2010).
  Medline CASGoogle Scholar
• 85 de Castro A, Concheiro M, Shakleya D et al. Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 33, 243–252 (2009).
  Medline CASGoogle Scholar
• 86 Kilman H. Umbilical cord. In: Encyclopedia of Reproduction, Volume 4. Knobil E, Neil J (Eds). Academic Press, CA, USA, 915–923 (1999).
  Google Scholar
• 87 Concheiro M, Shakleya D, Huestis MA. Simultaneous quantificatification of buprenorphine, norbuprenorphine, buprenorphine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry. Forensic Sci. Int 188, 144–151 (2009).
  Medline CASGoogle Scholar
• 88 Jones J, Rios R, Jones M et al. Determination of amphetamine and methamphetamine in umbilical cord using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 877, 3701–3706 (2009).
  Medline CASGoogle Scholar
• 89 De Castro A, Concheiro M, Shakleya DM et al. Development and validation of a liquid chromatography mass spectrometry assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. J. Chromatogr. B 877, 3065–3071 (2009).
  Medline CASGoogle Scholar
• 90 Chittama A, Marin SJ, Williams JA et al. Detection of in utero marijuana exposure by GC–MS, ultra-sensitive ELISA and LC–TOF–MS using umbilical cord tissue. J. Anal. Toxicol. 37, 391–394 (2013).
  MedlineGoogle Scholar
• 91 Marin SJ, Metcalf A, Krasowski MD et al. Detection of neonatal drug exposure using umbilical cord tissue and liquid chromatography time-of-flight mass spectrometry. Ther. Drug Monit 36, 119–124 (2014).
  Medline CASGoogle Scholar
• 92 Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin. Chim. Acta 370, 17–49 (2006).
  Medline CASGoogle Scholar
• 93 Lendoiro E, González-Colmenero E, Concheiro-Guisán A et al. Maternal hair analysis for the detection of illicit drugs, medicines, and alcohol exposure during pregnancy. Ther. Drug Monit 35, 296–304 (2013).
  Medline CASGoogle Scholar
• 94 Joya X, Gomez-Culebras M, Callejón A et al. Cocaine use during pregnancy assessed by hair analysis in a Canry Islands cohort. BMC Pregnancy Childbirth 12, 2–8 (2012).
  MedlineGoogle Scholar
• 95 Vincenti M, Salomone A, Gerace E et al. Role of LC–MS/MS in hair testing for the determination of common drugs of abuse and other psychoactive drugs. Bioanalysis 5(15), 1919–1938 (2013).
  CASGoogle Scholar
• 96 Crunelle CL, Yegles M, van Nuijs ALN et al. Hair ethyl glucuronide levels as a marker for alchol use and abuse: a review of the current state of art. Drug Alcohol Depend. 134, 1–11 (2014).
  Medline CASGoogle Scholar
• 97 Society of Hair Testing, Statement 2011. (2014). www.soht.org/index.php/statements/9-nicht-kategorisiert/85-statement-2011.
  Google Scholar
• 98 Favretto D, Stocchero G, Vogliardi S et al. Neonatal hair analysis by liquid chromatography-high resolution mass spectrometry to reveal gestational exposure to venlafaxine. Ther. Drug Monit. 32, 30–39 (2010).
  Medline CASGoogle Scholar
• 99 Frison G, Favretto D, Vogliardi S et al. Quantification of citalopram or escitalopram and their demethylated metabolites in neonatal hair samples by liquid chromatography-tandem mass spectrometry. Ther. Drug Monit. 30, 467–473 (2008).
  Medline CASGoogle Scholar
• 100 Goodwin RS, Wilkins DG, Averin O et al. Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration. Clin. Chem. 53(12), 2136–2143 (2007).
  Medline CASGoogle Scholar
• 101 Su PH, Chank YZ, Yang C et al. Perinatal effects of combined use of heroin, methadone, and amphetamine during pregnancy and quantitative measurement of metabolites in hair. Pediatr. Neonatol. 53, 112–117 (2012).
  MedlineGoogle Scholar
• 102 Aleksa K, Walasek P, Fulga N et al. Simultaneous detection of seventeen drugs of abuse and metabolites in hair using solid phase micro extraction (SPME) with GC/MS. Forensic Sci. Int. 218, 31–36 (2012).
  Medline CASGoogle Scholar
• 103 Köhlet E, Avenarius S, Rabsilber A et al. Nicotine and its metabolites in amniotic fluid at birth – assessment of prenatal tobacco smoke exposure. Hum. Exp. Toxicol. 29(5), 385–391 (2010).
  MedlineGoogle Scholar
• 104 Engelhart DA, Jenkins AJ. Detection of cocaine analytes and opiates in nails from postmortem cases. J. Anal. Toxicol. 26, 489–492 (2002).
  Medline CASGoogle Scholar
• 105 Mari F, Politi L, Bertol E. Nails of newborns in monitoring drug exposure during pregnancy. Forensic Sci. Int. 179, 176–180 (2008).
  Medline CASGoogle Scholar